#VELA investee co. #KNB Kanabo Group PLC – Partnership with BRITISH CANNABIS™ November 2, 2023 – Posted in: Vela Technologies Plc (VELA)

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce that it has entered into a partnership with BRITISH CANNABIS™ to supply the CBD by BRITISH CANNABIS™ range of pharmacy-grade CBD health supplements to patients via a prescription service through the Group’s online pain management clinic, Treat It.       The partnership will allow doctors to prescribe the CBD by BRITISH CANNABIS™ products…

Continue reading

#VELA investee co. #KNB Kanabo Group PLC – Appointment and Fundraiser May 9, 2023 – Posted in: Vela Technologies Plc (VELA)

Kanabo Group plc (LSE: KNB), the patient focused healthcare technology and cannabis company, is pleased to announce the completion of a fundraise (the “Fundraise”) to raise approximately £2.54 million via the issue of 88,194,443 new Ordinary Shares (“Fundraise Shares”). Additionally, the Company has also agreed to issue investors warrants to purchase up to 44,097,220 new Ordinary Shares. Participants in the fundraising include a new institutional investor as well as the Group’s recently appointed Non-Executive Chairman,…

Continue reading

#VELA Vela Technologies – Update re. #SGSC St George Street Capital COVID-19 trial August 18, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that St George Street Capital Ltd (“SGSC”), has today announced the publication in Lancet eClinicalMedicine of details of the ARCADIA clinical trial which investigated AZD1656 for people with diabetes and COVID-19.   Vela holds an economic interest in the commercialisation of AZD1656, details of which were included in the announcement published by Vela on 20 October…

Continue reading